

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | The membrane-bound transcription factor ATF6α plays a cytoprotective role in the unfolded protein response (UPR), required for cells to survive ER (endoplasmic reticulum) stress. Ceapin-A7 is a potent and selective inhibitor of ATF6α signaling in response to ER stress with an IC50 of 0.59 μM. Ceapin-A7 sensitized cells to ER stress. U2-OS cells co-incubated with both Tg and Ceapin-A7 showed an almost two-fold increase in sensitivity to ER stress (IC50 = 4.5 nM). Ceapin (0.6-18.9 μM; 4.5 hours) selectively inhibited ATF6α but not ATF6β[1]. |
| Concentration | Treated Time | Description | References | |
| A549 cells | 6 µM | 24 to 72 hours | Inhibited ATF6 cleavage, reduced virus titer | mSphere. 2021 Jun 30;6(3):e0036121. |
| Human chondrocytes | 500 nM | 24 hours | Inhibited ATF6 activation and reduced FGF2 expression | iScience. 2021 Jun 28;24(7):102791. |
| PBMCs | 6 µM | 1 hour | Inhibit ATF6 signaling pathway and reduce the expression of ATF6α | Mol Med. 2024 Nov 29;30(1):237. |
| RA FLSs | 1, 2, or 5 µM | 24 hours | Inhibited BIRC3 expression | Front Immunol. 2022 Oct 10;13:965708. |
| CD4+T cells | 6 µM | 1 hour | Inhibit ATF6 signaling pathway and reduce the differentiation of Th17 cells | Mol Med. 2024 Nov 29;30(1):237. |
| Bovine pulmonary artery endothelial cells (BPAEC) | 20 µM | 16, 20, 24, 36, 48 hours | To evaluate the effects of Ceapin-A7 on ATF6 activation and Cofilin phosphorylation. Ceapin-A7 reduced ATF6 activation and Cofilin phosphorylation. | Cell Signal. 2022 Nov;99:110432. |
| Bovine pulmonary artery endothelial cells (BPAEC) | 15 µM | 24 hours | To evaluate the effects of Ceapin-A7 on LPS-induced endothelial barrier dysfunction. Ceapin-A7 enhanced LPS-induced VE-cadherin internalization and barrier dysfunction. | Cell Signal. 2022 Nov;99:110432. |
| Bovine pulmonary artery endothelial cells (BPAEC) | 10, 15, 20 µM | 24 hours | To evaluate the effects of Ceapin-A7 on ATF6 activation and Cofilin phosphorylation. Ceapin-A7 decreased ATF6 activation and Cofilin phosphorylation. | Cell Signal. 2022 Nov;99:110432. |
| Bovine pulmonary artery endothelial cells (BPAEC) | 1–150 µM | 24 hours and 48 hours | To evaluate the effects of Ceapin-A7 on cell viability. Moderate doses (1–25 μM) were non-toxic, while higher doses (50–150 μM) reduced cell viability. | Cell Signal. 2022 Nov;99:110432. |
| 786-O cells | 20 µM | 5 hours | Inhibited ATF6 activation, reversed the increased expression of PINK1 and BNIP3 caused by NR3C1 knockdown. | J Transl Med. 2023 Oct 8;21(1):701. |
| ACHN cells | 20 µM | 5 hours | Inhibited ATF6 activation, reversed the increased expression of PINK1 and BNIP3, and the decreased expression of LC3 and increased expression of P62 caused by NR3C1 knockdown. | J Transl Med. 2023 Oct 8;21(1):701. |
| Administration | Dosage | Frequency | Description | References | ||
| SKG mice | Ankylosing spondylitis model | Oral administration in drinking water | 1 mM | Continuous administration until the end of the experiment | Reduced the number of vessels and osteophytes, inhibited angiogenesis-osteogenesis coupling | iScience. 2021 Jun 28;24(7):102791. |
| DBA/1J mice | Collagen-induced arthritis (CIA) model | Intraperitoneal injection | 10 mg/kg | Three times per week from days 22 to days 45 | Reduced arthritis severity and bone erosion | Front Immunol. 2022 Oct 10;13:965708. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.13mL 0.43mL 0.21mL |
10.63mL 2.13mL 1.06mL |
21.26mL 4.25mL 2.13mL |
|
| CAS号 | 2323027-38-7 |
| 分子式 | C20H12F6N4O3 |
| 分子量 | 470.32 |
| SMILES Code | O=C(C1=NOC(C2=CC=CO2)=C1)NC3=CN(CC4=CC=C(C(F)(F)F)C=C4C(F)(F)F)N=C3 |
| MDL No. | MFCD31567506 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | UJTDYOXTXGBHEG-UHFFFAOYSA-N |
| Pubchem ID | 154730128 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(223.25 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1